JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

Home・Akciju saraksts・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Slēgts

3.27 -2.97

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.21

Max

3.49

Galvenie mērījumi
By Trading Economics
Ienākumi	44M -26M
Pārdošana	-5.8M 42M
Peļņas marža	-61.388
Darbinieki	550
EBITDA	44M -22M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.11% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 17. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	159M 1.2B
Iepriekšējā atvēršanas cena	6.24
Iepriekšējā slēgšanas cena	3.27

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

2.02 / 2.115 Atbalsts un pretestība

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. febr. 23:11 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026. g. 3. febr. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026. g. 3. febr. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026. g. 3. febr. 23:38 UTC

Peļņas

AMD Sales Climb on Help From Data-Center Business -- Update

2026. g. 3. febr. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026. g. 3. febr. 23:27 UTC

Iegādes, apvienošanās, pārņemšana

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026. g. 3. febr. 23:25 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026. g. 3. febr. 23:23 UTC

Iegādes, apvienošanās, pārņemšana

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026. g. 3. febr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. febr. 22:56 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026. g. 3. febr. 22:40 UTC

Peļņas

Amdocs Extends Collaboration With T-Mobile

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Adj EPS $1.81

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Rev $1.16B

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q EPS $1.45 >

2026. g. 3. febr. 22:38 UTC

Peļņas

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026. g. 3. febr. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026. g. 3. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026. g. 3. febr. 22:14 UTC

Peļņas

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026. g. 3. febr. 22:13 UTC

Peļņas

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026. g. 3. febr. 22:12 UTC

Peļņas

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026. g. 3. febr. 22:10 UTC

Peļņas

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026. g. 3. febr. 22:10 UTC

Tirgus saruna

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

26.11% augšup

Prognoze 12 mēnešiem

Vidējais 4.25 USD 26.11%

Augstākais 4.5 USD

Zemākais 4 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.02 / 2.115Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.